Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte: Marie-Claire Taine

Marie-Claire Taine will join Veracyte on Sept. 19 as general manager of its in vitro diagnostics business unit, based in Marseille, France, with the task of leading the global expansion of Veracyte’s tests. She has 30 years of experience in the medical device and pharmaceutical industries. Most recently, she served as VP for renal care, Europe, and country sponsor, France, for Baxter International after having been president and general manager of the company’s French entity. Prior to Baxter, she served as senior VP of worldwide commercial operations for medical imaging company Guerbet; VP of venous solutions, EMEA, for Covidien; and general manager of ultrasound systems in France and North Africa for Siemens Medical Solutions. Taine earned a PhD in medical imaging from Paris XI-Orsay University. She also holds an engineering degree from Ecole Centrale de Lyon, a diploma from Institut de Formation Superieure Biomedicale-Villejuif, and an MBA from Institut d’Etudes Politiques Paris. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.